Ramón García‐Sánz

Research interests

Publications

• Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.21.00838

• Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30559-3

• COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

  Journal of Hematology & Oncology · 2021 · https://doi.org/10.1186/s13045-021-01177-0

• A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

  Blood · 2020 · https://doi.org/10.1182/blood.2020006844

• International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30309-2

• Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.01231

• Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1802917

• Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30072-x

• Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

  Leukemia · 2017 · https://doi.org/10.1038/leu.2017.29

• Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30632-5

• Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

  Blood · 2014 · https://doi.org/10.1182/blood-2014-01-550020

• International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.47.7901

• Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.199

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.196

• International prognostic scoring system for Waldenström macroglobulinemia

  Blood · 2009 · https://doi.org/10.1182/blood-2008-08-174961

• The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

  Annals of Oncology · 2009 · https://doi.org/10.1093/annonc/mdn796

• Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma

  Blood · 2007 · https://doi.org/10.1182/blood-2007-02-069625

• New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

  Blood · 2007 · https://doi.org/10.1182/blood-2007-05-088443

• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

  Blood · 2006 · https://doi.org/10.1182/blood-2006-04-019778

• Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.

  PubMed · 2005

• Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936

  Leukemia · 2003 · https://doi.org/10.1038/sj.leu.2403202

Current projects

No projects listed.